Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.39 |
| ▸ | TNF | P01375 | 2/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | EHMT2 | Q96KQ7 | 7/20 | 0.32 |
| ▸ | EHMT1 | Q9H9B1 | 7/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20838974 | 0.85 | PDE4D (0.44) | PDE4DTNFPDE10A | |
| SCHEMBL22264619 | 0.85 | PDE4D (0.44) | PDE4DTNFPDE10A | |
| SCHEMBL194991 | 0.83 | PDE4D (0.35) | PDE4DTNFEHMT2EHMT1PIK3CA | |
| SCHEMBL23068587 | 0.82 | PDE4D (0.47) | PDE4DTNFPDE10APIK3CAMAPK1 | |
| SCHEMBL30607013 | 0.82 | PDE4D (0.47) | PDE4DTNFPDE10APIK3CAMAPK1 | |
| SCHEMBL23068586 | 0.82 | PDE4D (0.47) | PDE4DTNFPDE10APIK3CAMAPK1 | |
| SCHEMBL10265576 | 0.82 | EML4 (0.36) | PDE4DTNFEHMT2EHMT1 | |
| SCHEMBL589081 | 0.82 | MAPT (0.38) | PDE4DMAPK1 | |
| SCHEMBL8059828 | 0.82 | PDE4D (0.40) | PDE4DTNFEHMT2EHMT1PIK3CA | |
| SCHEMBL12921249 | 0.81 | PDE4D (0.41) | PDE4DPDE10AEHMT2EHMT1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866445-B2 | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | UNION therapeutics A/S (DK) | 2024-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866445-B2 | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | PDE4A, PDE7A, PDE12 | PDE4D 11/4885TNF 969/4885PDE10A 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.